Journal Club

Management of Temozolomide Toxicity by Nurse Practitioners in Neuro-Oncology

Hanneke Zwinkels

Krista Roon

Frank J. F. Jeurissen

Martin J. B. Taphoorn

Wim C. J. Hop

Charles J. Vecht

cardiotoxicity, management
ONF 2009, 36(2), 225-231. DOI: 10.1188/09.ONF.225-231

Purpose/Objectives: To investigate the toxicity of temozolomide (TMZ) in patients with brain tumors and appropriate nursing interventions.

Design: Explorative analysis of prospective data.

Setting: A TMZ clinic led by a nurse practitioner (NP).

Sample: Group A (n = 71) received a standard dose of TMZ daily for five days 200 mg/m2 every four weeks; group B (n = 19) received a dose-intense schedule of TMZ daily for 21 days 75 mg/m2 every four weeks.

Methods: Toxicities were scored according to National Cancer Institute Common Terminology Criteria, and results in the two groups were compared.

Main Research Variables: Thrombopenia, neutropenia, and lymphopenia; nausea and vomiting; and NP interventions.

Findings: Of observed toxicities during six cycles, grade 3-4 thrombopenia was seen most frequently in group A. Neutropenia and subsequent interventions occurred more frequently in group A than in group B. Subsequent interventions consisted of dose delays and reductions. When patients were treated for a longer duration of time with TMZ, grade 3-4 lymphopenia occurred significantly more often in group B, necessitating Pneumocystis carinii pneumonia prophylaxis.

Conclusions: Degree of toxicity using a 5-day 200 mg/m2 or 21-day 75 mg/m2 schedule every four weeks was similar to that found in other studies.

Implications for Nursing: Through awareness of toxicity in relation to knowledge of brain tumors, NPs can become more effective in active management of TMZ toxicity.

Jump to a section

    References

    Bedell, C. H. (2003). A changing paradigm for cancer treatment: The advent of new oral chemotherapy agents. Clinical Journal of Oncology Nursing, 7(6, Suppl.), 5-9.
    Brandes, A. A., Tosoni, A., Cavallo, G., Bertorelle, R., Gioia, V., Franceschi, E., et al. (2006). Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: Phase II study from Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). British Journal of Cancer, 95(9), 1155-1160.
    Chang, S. M., Theodosopoulos, P., Lamborn, K., Malec, M., Rabbitt, J., Page, M., et al. (2004). Temozolomide in the treatment of recurrent malignant glioma. Cancer, 100(3), 605-611.
    Crighton, M. H. (2004). Dimensions of neutropenia in adult cancer patients: Expanding conceptualizations beyond the numerical value of the absolute neutrophil count. Cancer Nursing, 27(4), 275-284.
    Dutch Health Care Inspectorate. (2007). State of health report 2007. Retrieved January 7, 2008, from http://www.igz.nl/34044/Staat_van_de_Gezondheidszor1.pdf
    Gerber, D. E., Grossman, S. A., Zeltzman, M., Parisi, M. A., & Kleinberg, L. (2007). The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas. Neuro-Oncology, 9(1), 47-52.
    Hartigan, K. (2003). Patient education: The cornerstone of successful oral chemotherapy treatment. Clinical Journal of Oncology Nursing, 7(6, Suppl.), 21-24.
    Hollywood, E., & Semple, D. (2001). Nursing strategies for patients on oral chemotherapy. Oncology, 15(1, Suppl. 2), 37-39.
    Houston, D. (1997). Supportive therapies for cancer chemotherapy patients and the role of the oncology nurse. Cancer Nursing, 20(6), 409-413.
    Jen, J. F., Cutler, D. L., Pai, S. M., Batra, V. K., Affrime, M. B., Zambas, D. N., et al. (2000). Population pharmacokinetics of temozolomide in cancer patients. Pharmaceutical Research, 17(10), 1284-1289.
    Keime-Guibert, F., Chinot, O., Taillandier, L., Cartalat-Carel, S., Frenay, M., Kantor, G., et al. (2007). Radiotherapy for glioblastoma in the elderly. New England Journal of Medicine, 356(15), 1527-1535.
    Kristiansen, K., Hagen, S., Kollevold, T., Torvik, A., Holme, I., Nesbakken, R., et al. (1981). Combined modality therapy of operated astrocytomas grade III and IV. Confirmation of the value of postoperative irradiation and lack of potention of bleomycin on survival time: A prospective multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer, 47(4), 649-652.
    National Cancer Institute. (2003). Common Terminology Criteria for Adverse Events: Blood and bone marrow toxicity [version 3.0]. Bethesda, MD: Author.
    Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J., et al. (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New England Journal of Medicine, 352(10), 987-996.
    Su, Y. B., Sohn, S., Krown, S. E., Livingston, P. O., Wolchok, J. D., Quinn, C., et al. (2004). Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: A toxicity with therapeutic implications. Journal of Clinical Oncology, 22(4), 610-616.
    Taphoorn, M. J., Stupp, R., Coens, C., Osoba, D., Kortmann, R., van den Bent, M. J., et al. (2005). Health-related quality of life in patients with glioblastoma: A randomised controlled trial. Lancet Oncology, 6(12), 937-944.
    van den Bent, M. J., Taphoorn, M. J., Brandes, A. A., Menten, J., Stupp, R., Frenay, M., et al. (2003). Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: The European Organisation for Research and Treatment of Cancer Brain Tumor Group Study 26971. Journal of Clinical Oncology, 21(13), 2525-2528.
    Wick, A., Felsberg, J., Steinbach, J. P., Herrlinger, U., Platten, M., Blaschke, B., et al. (2007). Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. Journal of Clinical Oncology, 25(22), 3357-3361.